Notable Runner: A Reversal for Concordia International Corp Is Not Near. The Stock Reaches All-Time Low Today

Notable Runner: A Reversal for Concordia International Corp Is Not Near. The Stock Reaches All Time Low Today

The stock of Concordia International Corp (NASDAQ:CXRX) reached all time low today, Oct, 3 and still has $4.02 target or 14.00% below today’s $4.67 share price. This indicates more downside for the $228.56 million company. This technical setup was reported by If the $4.02 PT is reached, the company will be worth $32.00 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 472,162 shares traded hands. Concordia International Corp (NASDAQ:CXRX) has declined 84.59% since February 29, 2016 and is downtrending. It has underperformed by 96.80% the S&P500.

Analysts await Concordia International Corp (NASDAQ:CXRX) to report earnings on November, 10. They expect $1.35 earnings per share, up 3.05% or $0.04 from last year’s $1.31 per share. CXRX’s profit will be $66.07M for 0.86 P/E if the $1.35 EPS becomes a reality. After $1.21 actual earnings per share reported by Concordia International Corp for the previous quarter, Wall Street now forecasts 11.57% EPS growth.

Concordia International Corp (NASDAQ:CXRX) Ratings Coverage

Out of 9 analysts covering Concordia Healthcare Corp. (NASDAQ:CXRX), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. Concordia Healthcare Corp. has been the topic of 18 analyst reports since August 11, 2015 according to StockzIntelligence Inc. Laurentian maintained the stock with “Buy” rating in Tuesday, March 29 report. The firm has “Sector Perform” rating by Scotia Capital given on Monday, September 19. As per Thursday, August 4, the company rating was downgraded by TD Securities. Mackie upgraded Concordia International Corp (NASDAQ:CXRX) rating on Monday, October 19. Mackie has “Speculative Buy” rating and $42.50 price target. The rating was downgraded by GMP Securities to “Hold” on Monday, August 15. The firm has “Sector Outperform” rating by Scotia Capital given on Tuesday, September 29. S&P Research maintained Concordia International Corp (NASDAQ:CXRX) rating on Friday, October 16. S&P Research has “Buy” rating and $60 price target. As per Monday, June 6, the company rating was initiated by Goldman Sachs. The firm earned “Outperform” rating on Thursday, October 1 by RBC Capital Markets. Goldman Sachs maintained the stock with “Neutral” rating in Monday, August 15 report.

According to Zacks Investment Research, “Concordia International Corp is a diverse pharmaceutical company which focused on legacy pharmaceutical products and orphan drugs. The company also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin(R) for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications. Concordia International Corp, formerly known as Concordia Healthcare Corp, is headquartered in Oakville, Canada.”

More notable recent Concordia International Corp (NASDAQ:CXRX) news were published by: which released: “DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Concordia …” on September 29, 2016, also with their article: “Concordia International Corp takeover unlikely – Goldman” published on September 27, 2016, published: “STOCK LOSS ALERT: Rosen Law Firm Reminds Concordia International Corp …” on September 26, 2016. More interesting news about Concordia International Corp (NASDAQ:CXRX) were released by: and their article: “Shareholder Class Action Filed Against Concordia International Corp. – CXRX” published on August 17, 2016 as well as‘s news article titled: “Robbins Arroyo LLP: Concordia International Corp. (CXRX) Misled Shareholders …” with publication date: September 06, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment